TABLE 1.

Demographics and transplant characteristics of study participants

	De novo autoimmune hepatitis (n = 29)
Gender (m/f)	11/18
Ethnicity
Black	8
White	15
Hispanic	2
Asian	4
Age at transplant median (range) years	1.5 (0.2–12.3)
Graft type (n):
DD	24
LD	4
UNK	1
Induction therapy at time of transplant (n):
OKT3	0
ATG	0
sIL-2R antagonist	1
anti-CD52	0
Pre transplant diagnosis (n):
Biliary atresia	17
Acute liver failure	5
Metabolic	2
Other	5
Duration from transplant at DAIH diagnosis median (range) years:	5.3 (1.2 – 14.9)
Liver enzymes at diagnosis median (range):
ALT (5 – 45 IU/L)	108 (17 – 918)
GGT (5 – 32 IU/L)	72 (16 – 695)
Total bilirubin (<1 mg/dl)	0.7 (0.2 – 12.2)
Immunoglobulin G at diagnosis median (25–75% quartile): IgG (mg/dl)	1670 (1620 – 1910)
Calcineurin inhibitor at diagnosis (n):
Cyclosporine
Tacrolimus	13 16
Number of patients on steroids at diagnosis	5
Treatment once diagnosis made:
Steroid (mg/kg) (mean ± SD)	0.66 ± 0.68
Azathioprine (n)	14
Mycophenolate (n)	1
Sirolimus (n)	1
Number of exacerbations mean ± SD (n=17)	1.2 ± 1.4
Complications pre DAIH diagnosis (n):
Biliary	6
Arterial	0
Portal Vein	2
Hepatic Vein	1
CMV Infection	2
CMV Disease	1
PTLD	1
Episodes of Acute Cellular Rejection pre	14
DAIH diagnosis (n):
0	15
1	8
2	1
>2	4
Complications post DAIH diagnosis (n):
Re-listed	3
Re-transplanted	2
Portal hypertension	4
GFR < 60 ml/min/1.73m2	4
PTLD	0
CMV Infection	1
Death	1
Duration of follow up median (range) years	7.1 (1.6 – 15)

Reference values from Nelson Textbook of Pediatrics, 20^th Ed, chapter 727, 3464–3473.